124 related articles for article (PubMed ID: 10452255)
1. Expression of cholecystokinin-B/gastrin receptors in medullary thyroid cancer.
Amiri-Mosavi A; Ahlman H; Tisell LE; Wängberg B; Kölby L; Forssell-Aronsson E; Lundberg PA; Lindstedt G; Nilsson O
Eur J Surg; 1999 Jul; 165(7):628-31. PubMed ID: 10452255
[TBL] [Abstract][Full Text] [Related]
2. CCK receptors in human neuroendocrine tumors: clinical implications.
Reubi JC
Scand J Clin Lab Invest Suppl; 2001; 234():101-4. PubMed ID: 11713969
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
5. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT.
Bläker M; Arrenberg P; Stange I; Schulz M; Burghardt S; Michaelis H; Pace A; Greten H; von Schrenck T; de Weerth A
Regul Pept; 2004 Apr; 118(1-2):111-7. PubMed ID: 14759564
[TBL] [Abstract][Full Text] [Related]
6. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas.
Reubi JC; Waser B
Int J Cancer; 1996 Sep; 67(5):644-7. PubMed ID: 8782652
[TBL] [Abstract][Full Text] [Related]
7. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma.
Blaker M; de Weerth A; Tometten M; Schulz M; Höppner W; Arlt D; Hoang-Vu C; Dralle H; Terpe H; Jonas L; von Schrenck T
Eur J Endocrinol; 2002 Jan; 146(1):89-96. PubMed ID: 11751073
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer.
Konturek PC; Hartwich A; Zuchowicz M; Labza H; Pierzchalski P; Karczewska E; Bielanski W; Hahn EG; Konturek SJ
J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):737-49. PubMed ID: 11192946
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.
Reubi JC; Schaer JC; Waser B
Cancer Res; 1997 Apr; 57(7):1377-86. PubMed ID: 9102227
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines.
Monstein HJ; Ohlsson B; Axelson J
Scand J Gastroenterol; 2001 Jul; 36(7):738-43. PubMed ID: 11444473
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
Hartwich J; Konturek SJ; Pierzchalski P; Zuchowicz M; Konturek PC; Bielański W; Marlicz K; Starzyńska T; Ławniczak M
Med Sci Monit; 2001; 7(6):1171-81. PubMed ID: 11687726
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin 20 in thyroid carcinomas and peripheral blood detected by reverse transcription polymerase chain reaction.
Weber T; Lacroix J; Weitz J; Amnan K; Magener A; Hölting T; Klar E; Herfarth C; von Knebel Doeberitz M
Br J Cancer; 2000 Jan; 82(1):157-60. PubMed ID: 10638983
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
16. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
17. Structure and developmental expression of the mouse CCK-B receptor gene.
Lay JM; Jenkins C; Friis-Hansen L; Samuelson LC
Biochem Biophys Res Commun; 2000 Jun; 272(3):837-42. PubMed ID: 10860839
[TBL] [Abstract][Full Text] [Related]
18. Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma.
Tseleni-Balafouta S; Gakiopoulou H; Fanourakis G; Voutsinas G; Balafoutas D; Patsouris E
Exp Mol Pathol; 2006 Apr; 80(2):177-82. PubMed ID: 16259977
[TBL] [Abstract][Full Text] [Related]
19. Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma.
Takano T; Matsuzuka F; Sumizaki H; Kuma K; Amino N
Cancer Res; 1997 Sep; 57(17):3792-7. PubMed ID: 9288789
[TBL] [Abstract][Full Text] [Related]
20. Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma.
de Souza Meyer EL; Dora JM; Wagner MS; Maia AL
Clin Endocrinol (Oxf); 2005 Jun; 62(6):672-8. PubMed ID: 15943828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
